Head-to-head · free

AmerisourceBergen Corporation vs Abbott Laboratories

ABC vs ABT — return on capital, cash generation, margins and balance sheet side by side.

ABC

0 / 0

measures where ABC leads

ABT

0 / 0

measures where ABT leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureABCABT · FY2025
Revenue—$44.3B
Net income—$6.5B
Revenue growth (yearly, multi-year)—0.7%
Free cash flow—$7.4B
Free cash flow margin—16.7%
Net cash / (debt)——
ROIC—9.6%
Return on equity—13.1%
Gross margin—56.4%
Operating margin—18.2%
Net debt / EBITDA—0.39x

Figures are as reported by each company; latest fiscal year shown.

Where AmerisourceBergen Corporation's cash went

Not reported yet.

Full ABC profile →

Where Abbott Laboratories's cash went (FY2025)

Capital spending
$2.2B
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full ABT profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons